ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 79 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,179,031 | -74.5% | 222,040 | -54.3% | 0.00% | – |
| Q2 2023 | $4,631,368 | +24.7% | 485,978 | +43.9% | 0.00% | – |
| Q1 2023 | $3,714,194 | +26.7% | 337,654 | +70.5% | 0.00% | – |
| Q4 2022 | $2,931,347 | +22.8% | 198,064 | +58.5% | 0.00% | – |
| Q3 2022 | $2,387,000 | +3.6% | 124,926 | +15.5% | 0.00% | – |
| Q2 2022 | $2,304,000 | +22.7% | 108,169 | +11.0% | 0.00% | – |
| Q1 2022 | $1,878,000 | +70.9% | 97,452 | +83.8% | 0.00% | – |
| Q4 2021 | $1,099,000 | -68.0% | 53,019 | -63.1% | 0.00% | – |
| Q3 2021 | $3,434,000 | -44.5% | 143,746 | -36.6% | 0.00% | -100.0% |
| Q2 2021 | $6,185,000 | +70.1% | 226,673 | +80.3% | 0.00% | 0.0% |
| Q1 2021 | $3,636,000 | -15.0% | 125,712 | -17.3% | 0.00% | 0.0% |
| Q4 2020 | $4,277,000 | +5053.0% | 152,010 | +5323.1% | 0.00% | – |
| Q3 2020 | $83,000 | -23.1% | 2,803 | -21.6% | 0.00% | – |
| Q2 2020 | $108,000 | +151.2% | 3,573 | +148.6% | 0.00% | – |
| Q1 2020 | $43,000 | – | 1,437 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |